{Reference Type}: Journal Article
{Title}: Financial toxicity in patients with cancer: a cross-sectional study at an oncology hospital in central Vietnam.
{Author}: Tran BT;Tran TT;Dac QAN;Nguyen HL;Nguyen TX;Nguyen NPT;Nguyen TG;Le DD;Nguyen MT;
{Journal}: Support Care Cancer
{Volume}: 32
{Issue}: 9
{Year}: 2024 Aug 9
{Factor}: 3.359
{DOI}: 10.1007/s00520-024-08791-x
{Abstract}: OBJECTIVE: Cancer imposes a substantial financial burden on patients because of the high out-of-pocket expenses and the significant hardships. Financial toxicity describes the impact of cancer care costs at the patient level. Although the financial impact of cancer has been recognized, understanding the extent and determinants of financial toxicity in specific contexts is crucial. This study investigated the level of financial toxicity and its associated factors among patients with cancer at an oncology hospital in central Vietnam.
METHODS: This cross-sectional study included 334 patients with cancer. Direct interviews and medical record reviews were used for data collection. Financial toxicity was assessed using the 11-item Comprehensive Score for financial Toxicity (COST). A logistic regression model was used to determine factors associated with financial toxicity.
RESULTS: A notable 87.7% of patients experienced financial toxicity due to cancer cost, with 37.7% experiencing mild financial toxicity and 49.7% suffering from moderate financial toxicity, 0.3% reporting severe financial toxicity. Individuals with low household income exhibited a higher proportion of financial toxicity compared to that of those with higher income (odds ratio (OR)β=β5.78, 95% confidence interval (CI): 1.29-25.68). Compared with that of participants in the early stages, a higher burden was found in patients with advanced-stage cancer (ORβ=β3.88, 95% CI: 1.36-11.11).
CONCLUSIONS: Our study indicates that patients with cancer in Vietnam facefinancial toxicity. It is thus necessary for interventions to mitigate the financial burden on patients with cancer, focusing on vulnerable individuals and patients in the advanced stages.